Spots Global Cancer Trial Database for Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Official Title: Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.
Study ID: NCT01644968
Conditions
Study Description
Brief Summary: This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
Detailed Description: This study will evaluate the safety and determine the maximal tolerated dose of anti-OX40; evaluated the immune response to the study treatment; measure the pharmacokinetics of anti-OX40; monitor tumor regression, and identify the most biologically active dose of anti-OX40 to induce antigen-specific responses to a variety of immunogens.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Providence Cancer Center, Portland, Oregon, United States
Contact Details
Name: Brendan Curti, MD
Affiliation: Providence Health & Services
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
